Plant-based platform capitalize on Tiamat Sciences' plant-based production platform to offer cost-effective, scalable reagent supply for pharmaceutical developers seeking faster timelines and lower material costs.

Executive growth Target partnerships with rapidly scaling biotechs and pharma companies pursuing biologics, leveraging their recent hires in operations and strategy to streamline collaboration and accelerate contract execution.

Funding momentum Leverage the company’s funding history and investor backing to approach early-stage drug developers and contract manufacturers seeking credible, backed suppliers with growth potential.

Sustainability angle Emphasize decarbonized supply chain and plant-based manufacturing as a differentiator when selling to sustainability-focused teams and large pharma with ESG reporting needs.

Strategic collaborations Propose joint development or co-development deals around human growth factors and biologics, aligning with BIOMILQ and other partners already engaging with Tiamat’s platform.